STOCK TITAN

[Form 4] Walgreens Boots Alliance, Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Richard P. Gates, Senior Vice President and Chief Pharmacy Officer of Walgreens Boots Alliance (WBA), reported a transaction on 08/28/2025 disposing of 145,444 shares of Common Stock, leaving him with 0 shares beneficially owned following the reported transaction. The disposition reflects the treatment of restricted stock units (RSUs) at the closing of a merger: under the Merger Agreement dated March 6, 2025, each share of Common Stock was converted into $11.45 in cash plus one divested asset proceed right issued by the acquiror. RSUs were cancelled in exchange for that per-share consideration, with payment for any unvested RSUs conditioned on the recipient's continued service consistent with prior vesting terms.

Richard P. Gates, Senior Vice President e Chief Pharmacy Officer di Walgreens Boots Alliance (WBA), ha comunicato il 28/08/2025 la cessione di 145.444 azioni di azioni ordinarie, restando con 0 azioni di proprietà beneficiaria a seguito dell'operazione segnalata. La cessione deriva dal trattamento delle unità di azioni vincolate (RSU) alla chiusura di una fusione: in base all'Accordo di Fusione del 6 marzo 2025, ogni azione ordinaria è stata convertita in 11,45 $ in contanti più un diritto sui proventi di un bene dismesso emesso dall'acquirente. Le RSU sono state annullate in cambio di tale corrispettivo per azione, con il pagamento delle eventuali RSU non maturate subordinato alla continuazione del servizio del beneficiario, in conformità con i precedenti termini di maturazione.

Richard P. Gates, Vicepresidente Senior y Director de Farmacia de Walgreens Boots Alliance (WBA), informó el 28/08/2025 la enajenación de 145.444 acciones de acciones ordinarias, quedando con 0 acciones de propiedad beneficiaria tras la operación comunicada. La disposición responde al tratamiento de las unidades restringidas de acciones (RSU) al cierre de una fusión: según el Acuerdo de Fusión de fecha 6 de marzo de 2025, cada acción ordinaria se convirtió en 11,45 $ en efectivo más un derecho sobre los ingresos de un activo desinvertido emitido por el adquirente. Las RSU fueron canceladas a cambio de esa contraprestación por acción, quedando el pago de las RSU no devengadas condicionado a la continuidad en el servicio del beneficiario conforme a los términos previos de adquisición.

Richard P. Gates, Walgreens Boots Alliance(WBA)의 수석 부사장 겸 최고 약국 책임자는 2025년 8월 28일 보통주 145,444주를 처분했다고 보고했으며, 해당 거래 후 그가 실질적으로 보유한 주식은 0주입니다. 이 처분은 합병 종결 시 제한주식단위(RSU)에 대한 처리에 따른 것입니다. 2025년 3월 6일 체결된 합병계약에 따라 각 보통주는 인수회사에서 발행한 주당 11.45달러 현금하나의 자산 처분 수익권으로 전환되었습니다. RSU는 주당 이 보상과 교환되어 취소되었으며, 미확정(미베스팅) RSU에 대한 지급은 수령인이 이전의 베스팅 조건에 따라 계속 근무하는 경우로 조건화됩니다.

Richard P. Gates, vice-président principal et directeur pharmaceutique de Walgreens Boots Alliance (WBA), a déclaré le 28/08/2025 la cession de 145 444 actions ordinaires, le laissant avec 0 action détenue bénéficiairement après l'opération signalée. La cession résulte du traitement des unités d'actions restreintes (RSU) à la clôture d'une fusion : en vertu de l'accord de fusion en date du 6 mars 2025, chaque action ordinaire a été convertie en 11,45 $ en numéraire plus un droit sur le produit d'un actif cédé émis par l'acquéreur. Les RSU ont été annulées en échange de cette contrepartie par action, le paiement des RSU non acquises étant subordonné à la poursuite du service du bénéficiaire conformément aux conditions d'acquisition antérieures.

Richard P. Gates, Senior Vice President und Chief Pharmacy Officer von Walgreens Boots Alliance (WBA), meldete am 28.08.2025 die Veräußerung von 145.444 Aktien Stammaktien und hält nach der gemeldeten Transaktion 0 Aktien wirtschaftlich. Die Veräußerung ergibt sich aus der Behandlung von Restricted Stock Units (RSUs) zum Abschluss einer Fusion: gemäß dem Fusionsvertrag vom 6. März 2025 wurde jede Stammaktie in 11,45 $ in bar sowie ein Recht auf Erlöse aus einem veräußerten Vermögenswert ausgegeben vom Erwerber umgewandelt. Die RSUs wurden im Austausch gegen diese Vergütung pro Aktie annulliert; die Auszahlung für nicht unverfallte RSUs erfolgt nur bei fortgesetzter Dienstzeit des Empfängers gemäß den bisherigen Vesting-Bedingungen.

Positive
  • Transaction resulted from merger terms rather than an open‑market sale, clarifying it was not a liquidity-driven insider sale
  • Per-share cash consideration disclosed ($11.45 per share) provides clear valuation for converted equity
Negative
  • Reporting person no longer holds common stock after conversion, eliminating direct insider equity ownership in WBA
  • Economic upside on unvested RSUs remains conditional on continued employment, potentially limiting outright compensation realization

Insights

TL;DR: Insider holdings were eliminated by merger consideration, converting equity into cash and divested-asset rights; vesting for unvested RSUs remains service‑conditioned.

This Form 4 documents a post‑merger settlement of equity compensation rather than a voluntary open‑market sale. The reporting person’s 145,444 shares (including RSU equivalents) were treated per the Merger Agreement, which substituted cash and divested asset proceed rights for common shares. For governance and disclosure purposes this is a routine merger-related conversion that extinguishes direct share ownership but retains contingent economics on unvested RSUs tied to employment. Material investor implications relate to change in insider equity exposure following the corporate control transaction.

TL;DR: Transaction driven by merger terms; insider no longer holds common stock after automatic conversion into merger consideration.

The filing clarifies that the reported disposal is the mechanical result of the Merger’s effective conversion: each share converted into $11.45 cash plus a divested asset proceed right. This means the reporting person did not necessarily sell into the market; instead, equity was exchanged under the merger terms. Investors should note the specified per‑share cash figure and the existence of a divested asset proceed right as the economic replacement for common shares. Unvested RSU consideration remains subject to original vesting service requirements.

Richard P. Gates, Senior Vice President e Chief Pharmacy Officer di Walgreens Boots Alliance (WBA), ha comunicato il 28/08/2025 la cessione di 145.444 azioni di azioni ordinarie, restando con 0 azioni di proprietà beneficiaria a seguito dell'operazione segnalata. La cessione deriva dal trattamento delle unità di azioni vincolate (RSU) alla chiusura di una fusione: in base all'Accordo di Fusione del 6 marzo 2025, ogni azione ordinaria è stata convertita in 11,45 $ in contanti più un diritto sui proventi di un bene dismesso emesso dall'acquirente. Le RSU sono state annullate in cambio di tale corrispettivo per azione, con il pagamento delle eventuali RSU non maturate subordinato alla continuazione del servizio del beneficiario, in conformità con i precedenti termini di maturazione.

Richard P. Gates, Vicepresidente Senior y Director de Farmacia de Walgreens Boots Alliance (WBA), informó el 28/08/2025 la enajenación de 145.444 acciones de acciones ordinarias, quedando con 0 acciones de propiedad beneficiaria tras la operación comunicada. La disposición responde al tratamiento de las unidades restringidas de acciones (RSU) al cierre de una fusión: según el Acuerdo de Fusión de fecha 6 de marzo de 2025, cada acción ordinaria se convirtió en 11,45 $ en efectivo más un derecho sobre los ingresos de un activo desinvertido emitido por el adquirente. Las RSU fueron canceladas a cambio de esa contraprestación por acción, quedando el pago de las RSU no devengadas condicionado a la continuidad en el servicio del beneficiario conforme a los términos previos de adquisición.

Richard P. Gates, Walgreens Boots Alliance(WBA)의 수석 부사장 겸 최고 약국 책임자는 2025년 8월 28일 보통주 145,444주를 처분했다고 보고했으며, 해당 거래 후 그가 실질적으로 보유한 주식은 0주입니다. 이 처분은 합병 종결 시 제한주식단위(RSU)에 대한 처리에 따른 것입니다. 2025년 3월 6일 체결된 합병계약에 따라 각 보통주는 인수회사에서 발행한 주당 11.45달러 현금하나의 자산 처분 수익권으로 전환되었습니다. RSU는 주당 이 보상과 교환되어 취소되었으며, 미확정(미베스팅) RSU에 대한 지급은 수령인이 이전의 베스팅 조건에 따라 계속 근무하는 경우로 조건화됩니다.

Richard P. Gates, vice-président principal et directeur pharmaceutique de Walgreens Boots Alliance (WBA), a déclaré le 28/08/2025 la cession de 145 444 actions ordinaires, le laissant avec 0 action détenue bénéficiairement après l'opération signalée. La cession résulte du traitement des unités d'actions restreintes (RSU) à la clôture d'une fusion : en vertu de l'accord de fusion en date du 6 mars 2025, chaque action ordinaire a été convertie en 11,45 $ en numéraire plus un droit sur le produit d'un actif cédé émis par l'acquéreur. Les RSU ont été annulées en échange de cette contrepartie par action, le paiement des RSU non acquises étant subordonné à la poursuite du service du bénéficiaire conformément aux conditions d'acquisition antérieures.

Richard P. Gates, Senior Vice President und Chief Pharmacy Officer von Walgreens Boots Alliance (WBA), meldete am 28.08.2025 die Veräußerung von 145.444 Aktien Stammaktien und hält nach der gemeldeten Transaktion 0 Aktien wirtschaftlich. Die Veräußerung ergibt sich aus der Behandlung von Restricted Stock Units (RSUs) zum Abschluss einer Fusion: gemäß dem Fusionsvertrag vom 6. März 2025 wurde jede Stammaktie in 11,45 $ in bar sowie ein Recht auf Erlöse aus einem veräußerten Vermögenswert ausgegeben vom Erwerber umgewandelt. Die RSUs wurden im Austausch gegen diese Vergütung pro Aktie annulliert; die Auszahlung für nicht unverfallte RSUs erfolgt nur bei fortgesetzter Dienstzeit des Empfängers gemäß den bisherigen Vesting-Bedingungen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gates Richard P.

(Last) (First) (Middle)
C/O WALGREENS BOOTS ALLIANCE, INC.
108 WILMOT ROAD

(Street)
DEERFIELD IL 60015

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Walgreens Boots Alliance, Inc. [ WBA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Chief Pharmacy Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/28/2025 D 145,444(1) D (2)(3)(4) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Includes shares underlying restricted stock units ("RSUs"), inclusive of RSUs issued in lieu of dividends.
2. Pursuant to the Agreement and Plan of Merger, dated as of March 6, 2025 (the "Merger Agreement"), by and among Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), Blazing Star Parent, LLC, a Delaware limited liability company ("Parent"), Blazing Star Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), and the other affiliates of Parent named therein, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
3. At the effective time of the Merger (the "Effective Time") each share of Common Stock was automatically converted into the right to receive from Parent (i) $11.45 in cash, without interest thereon and subject to all applicable withholding (the "Per Share Cash Consideration"), and (ii) one divested asset proceed right issued by Parent or one of its affiliates subject to and in accordance with the divested asset proceed rights agreement (each, a "Divested Asset Proceed Right" and, collectively with the Per Share Cash Consideration, the "Per Share Consideration").
4. Pursuant to the Merger Agreement, each RSU owned by the reporting person at the Effective Time was cancelled in exchange for the Per Share Consideration, provided that, payment of such consideration with respect to any RSUs that were unvested as of the Effective Time will remain subject to the Reporting Person's continued service as an employee, consistent with the vesting conditions applicable to such RSU immediately prior to the Effective Time.
/s/ Richard Gates by Cherita Thomas, Attorney-in-Fact 08/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did Richard P. Gates report a disposition of 145,444 WBA shares on 08/28/2025?

The shares (including RSU equivalents) were cancelled and converted under the Merger Agreement into $11.45 in cash per share plus one divested asset proceed right, resulting from the merger effective at that time.

Does the Form 4 indicate an open‑market sale by Richard P. Gates?

No. The filing explains the disposition was due to the merger conversion of common stock and RSUs into the per‑share consideration, not an open‑market sale.

What happened to unvested RSUs owned by the reporting person?

Unvested RSUs were cancelled in exchange for the per‑share consideration, but payment for those RSUs remains subject to the reporting person’s continued service consistent with prior vesting conditions.

What was the cash component per share received in the merger?

The filing states the per‑share cash consideration was $11.45 per share, paid without interest and subject to applicable withholding.

What are divested asset proceed rights mentioned in the filing?

The filing refers to a Divested Asset Proceed Right issued by the acquiring parent or an affiliate as part of the per‑share consideration; the filing does not provide additional economic details about those rights.
Walgreen Boots

NASDAQ:WBA

WBA Rankings

WBA Latest News

WBA Latest SEC Filings

WBA Stock Data

10.37B
710.98M
17.44%
60.94%
2.67%
Pharmaceutical Retailers
Retail-drug Stores and Proprietary Stores
Link
United States
DEERFIELD